Irbesartan/Hydrochlorothiazide Axcount

Irbesartan/Hydrochlorothiazide, the active ingredient in Irbesartan/Hydrochlorothiazide Axcount, is an angiotensin II receptor blocker; thiazide diuretic presented as a tablet for oral use. It treats hypertension in adult patients. GNH USA supplies Irbesartan/Hydrochlorothiazide Axcount as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Irbesartan/Hydrochlorothiazide is used to manage high blood pressure within the antihypertensive drug class.

- Essential hypertension: lowers systolic and diastolic blood pressure to reduce cardiovascular risk. - Secondary hypertension: provides blood‑pressure control when hypertension is caused by another condition. - Hypertension in patients with diabetes: helps achieve target blood pressure while offering renal protective benefits.

Common Side Effects: - Dizziness or light‑headedness - Headache - Fatigue or weakness - Increased urination - Electrolyte disturbances (e.g., low potassium) - Mild gastrointestinal upset

Serious or Rare Side Effects: - Severe dehydration or electrolyte imbalance - Acute kidney injury - Hyperkalemia - Angioedema (swelling of face, lips, tongue) - Severe hypotension - Blood dyscrasias such as agranulocytosis

Before initiating therapy, clinicians should consider several safety measures. - Blood pressure monitoring: ensure adequate control and avoid excessive drops. - Renal function assessment: check serum creatinine and eGFR regularly. - Electrolyte surveillance: monitor potassium and sodium levels, especially with concomitant drugs. - Pregnancy: contraindicated in pregnancy (Category D) due to fetal risk. - Elderly patients: start at lower dose and monitor for orthostatic hypotension. - Store below 25°C: keep in the original container, protect from moisture and direct sunlight.

Irbesartan/Hydrochlorothiazide may interact with several medicines.

Major Interactions (Avoid): - Aliskiren: combined use can cause renal impairment and hyperkalemia. - Potassium‑sparing diuretics or supplements: risk of dangerous hyperkalemia. - Lithium: thiazide component can increase lithium levels and toxicity. - ACE inhibitors: additive effect on potassium and renal function. - NSAIDs: may blunt antihypertensive effect and impair renal function.

Moderate Interactions (Monitor Closely): - CYP2C9 inhibitors (e.g., fluconazole): may increase irbesartan plasma concentrations. - Other antihypertensives: additive blood‑pressure lowering effect, monitor for hypotension. - Antidiabetic agents: diuretic‑induced changes in glucose may require dose adjustment.